Impact of fluorodeoxyglucose PET on the management of esophageal cancer

Nuclear Medicine Communications

Volumn 30, Issue 2, 2009, Pages 95-116

  Salavati, Ali ^a   Basu, Sandip ^c,d   Heidari, Pedram ^b   Alavi, Abass ^c  

^a Medical Imaging Center   (Finland)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d TATA MEMORIAL HOSPITAL   (India)

Author keywords

18F fluorodeoxyglucose; Esophageal neoplasms; Neoadjuvant therapy; Neoplasm staging; Positron emission tomography; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 58549091530     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32831af204     Document Type: Review

References (195)

1. Parkin DM. International variation. Oncogens 2004; 23:6329-6340.
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83:18-29.
3. Schrump DS, Altorki NK, Forastiere AA, Minsky BD. Cancer of the esophagus. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology (6th ed). Philadelphia: Lippincott, Williams and Wilkins; 2001. pp. 1051-1091.
4. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007; 17:2-9.
5. Alderson D. Neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus. Clin Oncol 2001; 13:153-154.
6. Archer VR, Mulholland PJ, Stocken DD, Darnton SJ, Ferry DR. Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus. Clin Oncol 2001; 13:164-169.
7. Girling DJ, Bancewicz J, Clark PI, Smith DB, Donnelly RJ, Payers PM, et al. Surgical resection with or without preoperative chemotherapy In oesophageal cancer: a randomised controlled trial. Lancet 2002; 359:1727-1733.
8. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337:161-167.
9. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Qunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339:1979-1984.
10. American Joint Committee on Cancer. AJCC Cancer staging manual. New York: Springer-Verlag; 2002.
11. Lightdale CJ. Esophageal cancer. Am J Gastroenterol 1999; 94:20-29.
12. Van Westreenen HL, Heeren PA, Van Dullemen HM, Van der Jagt EJ, Jager PL, Groen H, et al. Positron emission tomography with F-18- fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg 2005; 9:54-61.
13. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sco U S A 2000; 97:9226-9233.
14. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med Mol Imaging 1996; 23:1409-1415.
15. Flanagan FL, Dehdashti F, Siegel BA. Staging of esophageal cancer with 18-F-fluorodexoglucose positron emission tomography. AJR Am J Roentgenol 1997; 64:770-777.
16. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997; 64:770-777.
17. Flamen P, Lerut A, Van Cutsem E, Gambier JP, Maes A, De Wever W, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 2000; 120:1085-1092.
18. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998; 78:521-527.
19. Meltzer CC, Luketich JD, Friedman D, Charron M, Strollo D, Meehan M, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 2000; 25:882-887.
20. 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004; 22:3805-3812.
21. Wren SM, Stijns P, Srinivas S, Stemmer EA, Stabile BE, Hansen P, et al. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 2002; 137:1001-1007.
22. Duong CP, Demitriou H, Weih L, Thompson A, Williams D, Thomas RJ, et al. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nuct Med Mol Imaging 2006; 33:759-769.
23. Bar-Shalom R, Guralnik L, Tsalic M, Leiderman M, Frenkel A, Gaitini D, et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 2005; 32:918-924.
24. Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS, Katholi CR, et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-D-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003; 125:938-944.
25. Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al. Esophageal cancer: results of American College of Surgeons patient care evaluation study. J Am Coll Surg 2000; 190:562-573.
26. Dellon ES, Shaheen NJ. Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival? J Clin Oncol 2005; 23:4478-4482.
27. Sharma P, Sidorenko EI. Are screening and surveillance for Barrett's oesophagus really worthwhile? Gut 2005; 54 (Suppl 1):i27-i32.
28. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127:310-330.
29. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138:176-186.
30. Oh DS, Hagen JA, Chandrasoma PT, Dunst CM, Demeester SR, Alavi M, et al. Clinical biology and surgical therapy of intramucosal adenocarcinoma of the esophagus. J Am Coll Surg 2006; 203:152-161.
31. 18F-fluorodeoxyglucose. Nippon Geka Gakkai zasshi 1994; 95:317-325.
32. Couper GW, McAteer D, Wallis F, Norton M, Welch A, Nicolson M, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998; 85:1403-1406.
33. Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202-3210.
34. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19:3058-3065.
35. Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998; 39:1002-1007.
36. Liberate G, Van Laethem JL, Gay F, Goldman S, Nagy N, Coppens E, et al. The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol 2004; 30:942-947.
37. Pfau PR, Perlman SB, Stanko P, Frick TJ, Gopal DV, Said A, et al. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc 2007; 65:377-384.
38. Little SG, Rice TW, Bybel B, Mason DP, Murthy SC, Falk GW, et al. Is FDG-PET indicated for superficial esophageal cancer? Eur J Cardiothorac Surg 2007; 31:791-796.
39. 18F-FDG uptake pattern in the stomach. J Nucl Med 2005; 46:48-51.
40. Bural GG, Kumar R, Mavi A, Alavi A. Reflux esophagitis secondary to chemotherapy detected by serial FDG-PET. Clin Nucl Med 2005; 30:182-183.
41. Bhargava P, Reich P, Alavi A, Zhuang H. Radiation-induced esophagitis on FDG PET imaging. Clin Nucl Med 2003; 28:849-850.
42. Shrikanthan S, Aydin A, Dhurairaj T, Alavi A, Zhuang H. Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging. Clin Nucl Med 2005; 30:695-697.
43. 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004; 45:1804-1810.
44. Bakheet SM, Amin T, Alia AG, Kuzo R, Powe J. F-18 FDG uptake in benign esophageal disease. Clin Nucl Med 1999; 24:995-997.
45. Himeno S, Yasuda S, Shimada H, Tajima T, Makuuchi H. Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol 2002; 32:340-346.
46. Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005; 103: 148-156.
47. Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 2006; 82:391-394; discussion 394-395.
48. Sihvo EI, Rasanen JV, Knuuti MJ, Minn HR, Luostarinen ME, Viljanen T, et al. Adenocarcinoma of the esophagus and the esophagogastric junction: positron emission tomography improves staging and prediction of survival in distant but not in locoregional disease. J Gastrointest Surg 2004; 8:988-996.
49. Flamen P, Lerut T, Haustermans K, Van Cutsem E, Mortelmans L. Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imaging 2004; 48:96-108.
50. Martin J, O'Connell RBW Jr, Edward Coleman R. PET in esophageal cancer. In: Ronald B, Workman REC, editors. PET/CT essentials for clinical practice. New York: Springer; 2006. pp. 143-157.
51. Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, et al. [18]FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 2008; 134:227-236.
52. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349:2241-2252.
53. Hulscher JBF, Tijssen JGP, Obertop H, Van Lanschot JJB. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a metaanalysis. Ann Thorac Surg 2001; 72:306-313.
54. Hulscher JBF, Van Sandick JW, De Boer AGEM, Wijnhoven BPL, Tijssen JGP, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347:1662-1669.
55. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185:538-543.
56. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462-467.
57. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8:226-234.
58. Raja SG, Salhiyyah K, Nagarajan K. Does neoadjuvant chemotherapy improve survival in patients with resectable thoracic oesophageal cancer? Interact Cardiovasc Thorac Surg 2007; 6:661-664.
59. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004; 91:540-551.
60. Imdahl A, Hentschel M, Kleimaier M, Hopt UT, Brink I. Impact of FDG-PET for staging of oesophageal cancer. Langenbecks Arch Surg 2004; 389:283-288.
61. Greil R, Stein HJ. Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer? Lancet Oncol 2007; 8:189-190.
62. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007; 8:545-553.
63. Wallace MB, Nietert PJ, Earle C, Krasna MJ, Hawes RH, Hoffman BJ, et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg 2002; 74:1026-1032.
64. Wijnhoven BPL, Pignatelli M, Dinjens WNM, Tilanus HW. Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction. J Surg Oncol 2005; 92:116-123.
65. Yamazaki K, Hasegawa M, Ohoka I, Hanami K, Asoh A, Nagao T, et al. Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma or the oesophagus. J Clin Path 2005; 58:904-910.
66. Rizk N, Downey RJ, Akhurst T, Gonen M, Bains MS, Larson S, et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 2006; 81:1076-1081.
67. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005; 130:151-159.
68. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23: 1136-1143.
69. Basu S, Alavi A. Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites? Eur J Nucl Med Mol Imaging 2007; 34:604-605.
70. Rice TW, Blackstone EH, Adelstein DJ, Zuccaro G Jr, Vargo JJ, Goldblum JR, et al. Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma. J Thorac Cardiovasc Surg 2003; 125:1091-1102.
71. Hunerbein M, Ulmer C, Handke T, Schlag PM. Endosonography of upper gastrointestinal tract cancer on demand using miniprobes or endoscopic ultrasound. Surg Endosc 2003; 17:615-619.
72. Heeren PAM, Van Westreenen HL, Geersing GJ, Van Dullemen HM, Plukker JTM. Influence of tumor characteristics on the accuracy of endoscopic ultrasonography in staging cancer of the esophagus and esophagogastric junction. Endoscopy 2004; 36:966-971.
73. May A, Gunter E, Roth F, Gossner L, Stolte M, Vieth M, et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut 2004; 53:634-640.
74. Lightdale CJ, Kulkarni KG. Role of endoscopie ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol 2005; 23: 4483-4489.
75. Rosch T. Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am 1995; 5:3537-3547.
76. Van Vliet EP, Eljkemans MJ, Kuipers EJ, Hermans JJ, Steyerberg EW, Tilanus HW, et al. A comparison between low-volume referring regional centers and a high-volume referral center in quality of preoperative metastasis detection in esophageal carcinoma. Am J Gastroenterol 2006; 101:234-242.
77. Fockens P, Van den Brande JHM, Van Dullemen HM, Van Lanschot JJB, Tytgat GNJ. Endosonographic T-staging of esophageal carcinoma: a learning curve. Gastrointest Endosc 1996; 44:58-62.
78. Meyers BF, Downey RJ, Decker PA, Keenan RJ, Siegel BA, Cerfolio RJ, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 2007; 133:738-745.
79. Van Westreenen HL, Westerterp M, Sloof GW, Groen H, Bossuyt PM, Jager PL, et al. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg 2007; 94:1515-1520.
80. Lowe VJ, Booya F, Fletcher JG, Nathan M, Jensen E, Mullan B, et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 2005; 7:422-430.
81. Fockens P, Kisman K, Merkus MP, Van Jan Lanschot J, Hugo Obertop C, Tytgat GNJ. The prognosis of esophageal carcinoma staged irresectable (T4) by endosonography. J Am Coll Surg 1998; 186:17-23.
82. Roder JD, Busch R, Stein HJ, Fink U, Siewert JR. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 1994; 81:410-413.
83. DeMeester SR. Lymph node involvement in esophageal adenocarcinoma: if you see one, have you seen them all? J Thorac Cardiovasc Surg 2003; 126:947-949.
84. DeMeester TR. Esophageal carcinoma: current controversies. Semin Surg Oncol 1997; 13:217-233.
85. Patel AN, Buenaventura PO. Current staging of esophageal carcinoma. Surg Oncol Clin N Am 2005; 85:555-567.
86. Hagen JA, DeMeester TR. Staging of esophageal carcinoma. J Thorac Cardiovasc Surg 2003; 125:988-991.
87. Forastiere AA, Heitmiller RF, Lee DJ, Zahurak M, Abrams R, Kleinberg L, et al. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. Cancer J Sci Am 1997; 3:144-152.
88. Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 1993; 11: 1118-1123.
89. Plukker JT, Van Westreenen H L. Staging in oesophageal cancer. Best Pract Res Clin Gastroenterol 2006; 20:877-891.
90. Kelly S, Harris KM, Berry E, Hutton J, Roderick P, Cullingworth J, et al. A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut 2001; 49:834-539.
91. Van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008; 3:547-557.
92. Eloubeidi MA, Wallace MB, Reed CE, Hadzijahio N, Lewin DN, Van Velse A, et al. The utility of EUS and EUS-guided fine needle aspiration in detecting celiac lymph node metastasis in patients with esophageal cancer: a single-center experience. Gastmintest Endosc 2001; 54:714-719.
93. Giovannini M, Monges G, Seitz JF, Moutardier V, Bernardini D, Thomas P, et al. Distant lymph node metastases in esophageal cancer: Impact of endoscopic ultrasound-guided biopsy. Endoscopy 1999; 31:536-540.
94. Vazquez-Sequeiros E, Wlersema MJ, Clain JE, Norton ID, Levy MJ, Romero Y, et al. Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology 2003; 125:1626-1635.
95. Reed CE, Mishra G, Sahai AV, Hoffman BJ, Hawes RH. Esophageal cancer staging: improved accuracy by endoscopic ultrasound of celiac lymph nodes. Ann Thorac Surg 1999; 67:319-322.
96. Rice TW. Clinical staging of esophageal carcinoma: CT, EUS, and PET. Chest Surg Clin N Am 2000; 10:471-485.
97. Salminen JT, Farkkila MA, Ramo OJ, Toikkanen V, Simpanen J, Nuutinen H, et al. Endoscopic ultrasonography in the preoperative staging of adenocarcinoma of the distal oesophagus and oesophagogastric junction. Scand J Gastroenterol 1999; 34:1178-1182.
98. Wiersema MJ, Vilmann P, Giovannini M. Prospective multicenter evaluation of EUS-guided fine needle aspiration biopsy (FNA): diagnostic accuracy and complication. Gastrointest Endosc 1996; 4:1087-1095.
99. Catalane MF, Alcocer E, Chak A, Nguyen CC, Raijman I, Geenen JE, et al. Evaluation of metastatic celiac axis lymph nodes in patients with esophageal carcinoma: accuracy of EUS. Gastrointest Endosc 1999; 50:352-356.
100. Pellise M, Castells A, Gines A, Agrelo R, Sole M, Castellvi-Bel S, et al. Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonography-guided fine-needle aspiration biopsy. Clin Cancer Res 2004; 10:4444-4449.
101. Chen VK, Eloubeidi MA. Endoscopic ultrasound-guided fine needle aspiration is superior to lymph node echofeatures: a prospective evaluation of mediastinal and peri-intestinal lymphadenopathy. Am J Gastroenterol 2004; 99:628-633.
102. Wu LF, Wang BZ, Feng JL, Cheng WR, Liu GR, Xu XH, et al. Preoperative TN staging of esophageal cancer: comparison of miniprobe ultrasonography, spiral CT and MRI. World J Gastroenterol 2003; 9: 219-224.
103. Nishimaki T, Tanaka O, Ando N, Ide H, Watanabe H, Shinoda M, et al. Evaluation of the accuracy of preoperative staging in thoracic esophageal cancer. Ann Thorac Surg 1999; 68:2059-2064.
104. Yoshikane H, Tsukamoto Y, Niwa Y, Goto H, Hase S, Shimodaira M, et al. Superficial esophageal carcinoma: evaluation by endoscopic ultrasonography. Am J Gastroenterol 1994; 89:702-707.
105. Greenberg J, Durkin M, Van Drunen M, Aranha GV. Computed tomography or endoscopic ultrasonography in preoperative staging of gastric and esophageal tumors. Surgery 1994; 116:696-701; discussion 701-702.
106. Sondenaa K, Skaane P, Nygaard K, Skjennald A. Value of computed tomography in preoperative evaluation of resectability and staging in oesophageal carcinoma. Eur J Surg 1992; 158:537-540.
107. Ziegler K, Sanft C, Zeitz M, Friedrich M, Stein H, Haring R, et al. Evaluation of endosonography in TN staging of oesophageal cancer. Gut 1991; 32:16-20.
108. Botet JF, Lightdale CJ, Zauber AG, Gerdes H, Urmacher C, Brennan MF. Preoperative staging of esophageal cancer: comparison of endoscopic US and dynamic CT. Radiology 1991; 181:419-425.
109. Yoon YC, Lee KS, Shim YM, Kim BT, Kim K, Kim TS. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology 2003; 227:764-770.
110. Choi JY, Lee KH, Shim YM, Lee KS, Kim JJ, Kim SE, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000; 41:808-815.
111. Yeung HWD, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in esophageal cancer: incremental value over computed tomography. Clin Positron Imaging 1999; 2:255-260.
112. Rasanen JV, Sihvo EIT, Knuuti MJ, Minn HRI, Luostarinen MES, Laippala P, et al. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 2003; 10:954-960.
113. Luketich JD, Schauer PR, Meltzer CC, Landreneau RJ, Urso GK, Townsend DW, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 1997; 64:765-769.
114. Lerut T, Flamen P, Ectors N, Van Cutsem E, Peeters M, Hiele M, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000; 232:743-752.
115. Rankin SC, Taylor H, Cook GJR, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 1998; 53:659-665.
116. 18F- fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer 1999; 86:1638-1648.
117. Jager PL, Que TH, Vaalburg W, Pruim J, Elsinga P, Plukker JT. Carbon-11 choline or FDG-PET for staging of oesophageal cancer? Eur J Nucl Med Mol Imaging 2001; 28:1845-1849.
118. Junginger T, Kneist W, Schreckenberger M, Menzel C, Oberholzer K, Bartenstein P. Positron emission tomography for the preoperative staging of esophageal carcinoma. Dtsch Med Wochenschr 2002; 127: 1935-1941.
119. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002; 94:921-928.
120. Westerterp M, Van Westreenen HL, Sloof GW, Plukker JT, Van Lanschot JJ. Role of positron emission tomography in the (re-)staging of oesophageal cancer. Scand J Gastroenterol Suppl 2006; 243:116-122.
121. Kneist W, Schreckenberger M, Bartenstein P, Grunwald F, Oberholzer K, Junginger T. Positron emission tomography for staging esophageal cancer: does it lead to a different therapeutic approach? World J Surg 2003; 27:1105-1112.
122. Lachs MS, Nachamkin I, Edelstein PH, Goldman J, Feinstein AR, Schwartz JS. Spectrum bias in the evaluation of diagnostic tests: lessons from the rapid dipstick test for urinary tract infection. Ann Intern Med 1992; 117:35-140.
123. Thompson WM. Esophageal carcinoma. Abdom Imaging 1997; 22: 138-142.
124. Van Westreenen HL, Heeren PAM, Jager PL, Van Dullemen HM, Groen H, Plukker JTM. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol 2003; 10:1100-1105.
125. Yuan S, Yu Y, Chao KS, Fu Z, Yin Y, Liu T, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 2006; 47: 1255-1259.
126. Bar-Shalom R, Leiderman M, Gaitini D. The value of PET/CT using FDG in patients with esophageal cancer. J Nucl Med 2003; 44:21.
127. Hadzijahic N, Wallace MB, Hawes RH, VanVelse A, LeVeen M, Marsi V, et al. CT or EUS for the initial staging of esophageal cancer? A cost minimization analysis. Gasfrointest Endosc 2000; 52:715-720.
128. Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer 1996; 78:1820-1828.
129. Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999; 68:1133-1137.
130. Van Vliet EP, Steyerberg EW, Eijkemans MJ, Kuipers EJ, Siersema PD. Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis. Br J Cancer 2007; 97: 868-876.
131. Van Vliet EP, Van der Lugt A, Kuipers EJ, Tilanus HW, Van der Gaast A, Hermans JJ, et al. Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study. J Surg Oncol 2007; 96:200-206.
132. Kneist W, Schreckenberger M, Bartenstein P, Menzel C, Oberholzer K, Junginger T. Prospective evaluation of positron emission tomography in the preoperative staging of esophageal carcinoma. Arch Surg 2004; 139:1043-1049.
133. 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003; 21:428-432.
134. Lerut T. Esophageal surgery at the end of the millennium. J Thorac Cardiovasc Surg 1998; 116:1-20.
135. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002; 183:274-279.
136. Lerut T, Coosemans W, Decker G, De Leyn P, Nafteux P, Van Raemdonck D. Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies. Surg Oncol 2001; 10:113-122.
137. Stein HJ, Feith M, Siewert JR. Cancer of the esophagogastric junction. Surg Oncol 2000; 9:35-41.
138. Malthaner RA, Wong RKS, Rumble RB, Zuraw L, Agboola O, Citron M, et al. Neoadjuvant or adjuvant therapy for respectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004; 2:35-52.
139. Wayman J, Bennett MK, Raimes SA, Griffin SM. The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer 2002; 86:1223-1229.
140. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91: 2165-2174.
141. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114:210-217.
142. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988; 96:242-248.
143. Van Raemdonck D, Van Cutsem E, Menten J, Ectors N, Coosemans W, De Leyn P, et al. Induction therapy for clinical T4 oesophageal carcinoma; a plea for continued surgical exploration. Eur J Cardiothorac Surg 1997; 11:828-837.
144. Dehdashti F, Siegel BA. Neoplasms of the esophagus and stomach. Semin Nucl Med 2004; 34:198-208.
145. Walsh TN, Grannell M, Mansoor S. Predictive factors for success of neoadjuvant therapy in upper gastrointestinal cancer. J Gastroenterol Hepatol 2002; 17 (Suppl):S172-S175.
146. Griffith JF, Chan ACW, Chow LTC, Leung SF, Lam YH, Liang EY, et al. Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT. Br J Radiol 1999; 72:678-684.
147. Jones DR, Parker LA Jr, Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999; 85: 1026-1032.
148. Walker SJ, Allen SM, Steel A, Cullen MH, Matthews HR. Assessment of the response to chemotherapy in oesophageal cancer. Eur J Cardiothorac Surg 1991; 5:519-522.
149. Westerterp M, Van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 2005; 236:841-851.
150. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Boubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 2005; 129:1232-1241.
151. Hordijk ML, Kok TC, Wilson JHP, Mulder AH. Assessment of response of esophageal carcinoma to induction chemotherapy. Endoscopy 1993; 25:592-596.
152. Zuccaro G Jr, Rice TW, Goldblum J, Medendorp SV, Becker M, Pimentel R, et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 1999; 94:906-912.
153. Beseth BD, Bedford R, Isacoff WH, Holmes EC, Cameron RB. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 2000; 66:827-831.
154. Bowrey DJ, Clark GWB, Roberts SA, Hawthorne AB, Maughan TS, Williams GT, et al. Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus. J Gastrointest Surg 1999; 3:462-467.
155. Kalha I, Kaw M, Fukami N, Patel M, Singh S, Gagneja H, et al. The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. Cancer 2004; 101:940-947.
156. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004; 78:1152-1160.
157. Chak A, Canto MI, Cooper GS, Isenberg G, Willis J, Levitan N, et al. Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer 2000; 88:1788-1795.
158. Hirata N, Kawamoto K, Ueyama T, Masuda K, Utsunomiya T, Kuwano H. Using endosonography to assess the effects of neoadjuvant therapy in patients with advanced esophageal cancer. AJR Am J Roentgenol 1997; 169:485-491.
159. Willis J, Cooper GS, Isenberg G, Sivak MV Jr, Levitan N, Clayman J, et al. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointest Endosc 2002; 55:655-661.
160. Rice TW, Boyce GA, Sivak MV, Adelstein DJ, Kirby TJ. Esophageal carcinoma: esophageal ultrasound assessment of preoperative chemotherapy. Ann Thorac Surg 1992; 53:972-977.
161. Brucher BLDM, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001; 233: 300-309.
162. Flamen P, Van Cutsem E, Lerut A, Gambier J P, Haustermans K, Bormans G, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002; 13:361-368.
163. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002; 184:279-283.
164. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73:2680-2686.
165. 18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002; 4:301-310.
166. 18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imag Biol 2003; 5:337-346.
167. Wieder HA, Brucher BLDM, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22:900-908.
168. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35:1773-1782.
169. Erasmus JJ, Munden RF. The role of Integrated computed tomography positron-emission tomography in esophageal cancer: staging and assessment of therapeutic response. Semin Radiat Oncol 2007; 17:29-37.
170. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999; 40:1771-1777.
171. Basu S, Alavi A. Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging 2007; 34:441-443.
172. Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, et al. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol 2006; 1:478-486.
173. Basu S, Alavi A. Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging 2007; 34:1527-1529.
174. Roubein LD, DuBrow R, David C, Lynch P, Fornage B, Ajani J, et al. Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the esophagus and esophagogastnc junction. Endoscopy 1993; 25:587-591.
175. Katlic MR, Wilkins EW Jr, Grillo HC. Three decades of treatment of esophageal squamous carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg 1990; 99:929-938.
176. Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996; 14:156-163.
177. Flood WA, Forastiere AA. Esophageal cancer. In: Benson AB III, editors. Gastrointestinal oncology. Amsterdam: Kluwer Academic Publishers; 1998. pp. 1-40.
178. Duong CP, Hicks RJ, Weih L, Drummond E, Leong T, Michael M, et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging 2006; 33:770-778.
179. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, et al. 2-Fluoro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004; 101:1776- 1785.
180. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med 2004; 45:1843-1850.
181. Van Westreenen HL, Plukker JT, Cobben DC, Verhoogt CJ, Groen H, Jager PL. Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol 2005; 185:436-440.
182. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24:4692-4698.
183. Basu S, Alavi A. Staging with PET and the 'Will Rogers' effect: redefining prognosis and survival in patients with cancer. Eur J Nucl Med Mol Imaging 2008; 35:1-4.
184. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312:1604-1608.
185. Altorki NK, Girardi L, Skinner DB, Trastek VF, Krasna M. En bloc esophagectomy improves survival for stage III esophageal cancer. J Thorac Cardiovasc Surg 1997; 114:948-956.
186. Baba M, Aikou T, Yoshlnaka H, Natsugoe S, Fukumoto T, Shimazu H, et al. Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 1994; 219:310-316.
187. Nigro JJ, DeMeester SR, Hagen JA, DeMeester TR, Peters JH, Kiyabu M, et al. Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. J Thorac Cardiovasc Surg 1999; 117: 960-968.
188. Fahn HJ, Wang LS, Huang BS, Huang MH, Chien KY. Tumour recurrence in long-term survivors after treatment of carcinoma of the esophagus. Ann Thorac Surg 1994; 57:669-676.
189. Mantravadi RVP, Lad T, Briele H, Liebner EJ. Carcinoma of the esophagus: sites of failure. Int J Radiat Oncol Biol Phys 1982; 8:1897-1901.
190. Van Lanschot JJB, Tilanus HW, Voormolen MHJ, Van Deelen RAJ. Recurrence pattern of oesophageal carcinoma after limited resection does not support wide local excision with extensive lymph node dissection. Br J Surg 1994; 81:1320-1323.
191. Raoul JL, Le Prise E, Meunier B, Julienne V, Etienne PL, Gosselin M, et al. Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut 1995; 37:174-176.
192. Carlisle JG, Quint LE, Francis IR, Orringer MB, Smick JF, Gross BH. Recurrent esophageal carcinoma: CT evaluation after esophagectomy. Radiology 1993; 189:271-275.
193. Pierie JPEN, De Graaf PW, Poen H, Van der Tweel I, Obertop H. Incidence and management of benign anastomotic stricture after cervical oesophagogastrostomy. Br J Surg 1993; 80:471-474.
194. Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Kuwano H. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 2004; 91:1004-1009.
195. Von Rahden BH, Sarbia M, Stein HJ. Medical image. Combined FDG-PET/ CT and CT-guided biopsy in diagnosing oesophageal cancer recurrence. N Z Med J 2006; 119:U1810.